The latest price target for NexImmune (OTCPK:NEXI) was reported by Cantor Fitzgerald on November 16, 2022. The analyst firm set a price target for $0.00 expecting NEXI to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for NexImmune (OTCPK:NEXI) was provided by Cantor Fitzgerald, and NexImmune downgraded their neutral rating.

There is no last upgrade for NexImmune

The last downgrade for NexImmune Inc happened on November 16, 2022 when Cantor Fitzgerald changed their price target from N/A to N/A for NexImmune Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NexImmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NexImmune was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.

While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a downgraded with a price target of $0.00 to $0.00. The current price NexImmune (NEXI) is trading at is $0.33, which is out of the analyst’s predicted range.